Aileron Therapeutics to Present at the Canaccord Genuity 44th Annual Growth Conference

Rhea-AI Summary

Aileron Therapeutics (NASDAQ: ALRN), a biopharmaceutical company focused on developing first-in-class medicines for orphan pulmonary and fibrosis indications, has announced its participation in the Canaccord Genuity 44th Annual Growth Conference. The company's President and CEO, Brian Windsor, Ph.D., is scheduled to present on Tuesday, August 13, 2024, at 4:00 p.m. EDT in Boston, MA.

Investors and interested parties can access a live webcast of the presentation through Aileron's investor relations website. The webcast replay will remain available for 90 days following the event, providing an opportunity for those unable to attend the live presentation to catch up on Aileron's latest developments and future plans.

News Market Reaction

-0.86%

1 alert

-0.86% News Effect

On the day this news was published, ALRN declined 0.86%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AUSTIN, Texas, July 30, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that Brian Windsor, Ph.D., President and Chief Executive Officer, will present at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024 at 4:00 p.m. EDT in Boston, MA.

A live webcast of the event can be accessed at https://investors.aileronrx.com/events-presentations/investor-events. A replay of the webcast will be available for 90 days following the presentation.

About Aileron Therapeutics

Aileron Therapeutics, Inc. is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Aileron's lead product candidate, LTI-03, is a novel, synthetic peptide with a dual mechanism targeting alveolar epithelial cell survival as well as inhibition of profibrotic signaling. Currently, LTI-03 is being evaluated in a Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis. Aileron's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US.

Investor Relations & Media Contact:
Argot Partners
aileron@argotpartners.com
212-600-1902

View original content to download multimedia:https://www.prnewswire.com/news-releases/aileron-therapeutics-to-present-at-the-canaccord-genuity-44th-annual-growth-conference-302208743.html

SOURCE Aileron Therapeutics, Inc.

FAQ

When is Aileron Therapeutics (ALRN) presenting at the Canaccord Genuity 44th Annual Growth Conference?

Aileron Therapeutics (ALRN) is presenting at the Canaccord Genuity 44th Annual Growth Conference on Tuesday, August 13, 2024, at 4:00 p.m. EDT in Boston, MA.

Who will be presenting for Aileron Therapeutics (ALRN) at the Canaccord Genuity conference?

Brian Windsor, Ph.D., President and Chief Executive Officer of Aileron Therapeutics, will be presenting at the Canaccord Genuity conference.

How can investors access Aileron Therapeutics' (ALRN) presentation at the Canaccord Genuity conference?

Investors can access a live webcast of Aileron Therapeutics' presentation through the company's investor relations website at https://investors.aileronrx.com/events-presentations/investor-events.

How long will the replay of Aileron Therapeutics' (ALRN) presentation be available?

The replay of Aileron Therapeutics' presentation will be available for 90 days following the event on August 13, 2024.

What is the focus of Aileron Therapeutics' (ALRN) drug development pipeline?

Aileron Therapeutics is advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications.